Company Captor Therapeutics Spolka Akcyjna

Equities

CTX

PLCPTRT00014

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Captor Therapeutics Spolka Akcyjna

Chiffre d''affaires - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:58:18 2024-04-19 am EDT			5-day change	1st Jan Change
80.2 ^PLN	-2.67%		-0.99%	-18.99%

2023	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

Number of employees: 111

PLN in Million	2022	Weight	2023	Weight	Delta
Research and Development 100.0 %	9	100.0 %	13	100.0 %	+44.15%

PLN in Million	2022	Weight	2023	Weight	Delta
Poland 100.0 %	9	100.0 %	13	100.0 %	+44.15%

Managers	Title	Age	Since
Thomas Shepherd CEO	Chief Executive Officer	-	-
Radoslaw Krawczyk DFI	Director of Finance/CFO	-	21-05-31
Michal Jerzy Walczak CTO	Chief Tech/Sci/R&D Officer	39	19-11-21
Maria Sagan IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Krzysztof Samotij BRD	Director/Board Member	72	20-04-07
Robert Florczykowski BRD	Director/Board Member	-	21-12-31
Pawel Jerzy Holstinghausen-Holsten CHM	Chairman	52	18-08-27
Maciej Wroblewski BRD	Director/Board Member	-	21-03-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,645,712	2,353,229 ( 50.65 %)	0	50.65 %

Name	Equities	%	Valuation
Generali PTE SA 3.110 %	144,460	3.110 %	2 M zł
Allianz Polska TFI SA 2.021 %	93,910	2.021 %	1 M zł
Skarbiec TFI SA 0.5979 %	27,778	0.5979 %	438 847 zł
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA 0.2673 %	12,416	0.2673 %	196 153 zł
Pekao TFI SA 0.2154 %	10,009	0.2154 %	158 126 zł
Investors TFI SA 0.1216 %	5,650	0.1216 %	89 261 zł

Captor Therapeutics SA

ul. Dunska 11

54-427, Wroclaw

+48 53 786 9089

http://www.captortherapeutics.com

address Captor Therapeutics Spolka Akcyjna(CTX)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

82.4 PLN

Average target price

115 PLN

Spread / Average Target

+39.56%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CAPTOR THERAPEUTICS SPOLKA AKCYJNA	-18.99%	94.25M
IQVIA HOLDINGS INC.	-2.16%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.38%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.64%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.95%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.93%	11.68B
MEDPACE HOLDINGS, INC.	+20.52%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.82%	11.15B

Other Biotechnology & Medical Research